PL3302499T3 - Leczenie chorób mitochondrialnych - Google Patents
Leczenie chorób mitochondrialnychInfo
- Publication number
- PL3302499T3 PL3302499T3 PL16728892.7T PL16728892T PL3302499T3 PL 3302499 T3 PL3302499 T3 PL 3302499T3 PL 16728892 T PL16728892 T PL 16728892T PL 3302499 T3 PL3302499 T3 PL 3302499T3
- Authority
- PL
- Poland
- Prior art keywords
- treatment
- mitochondrial diseases
- mitochondrial
- diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C1/00—Preparation of hydrocarbons from one or more compounds, none of them being a hydrocarbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15170825 | 2015-06-05 | ||
| PCT/EP2016/062636 WO2016193421A1 (en) | 2015-06-05 | 2016-06-03 | Treatment of mitochondrial diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3302499T3 true PL3302499T3 (pl) | 2023-07-24 |
Family
ID=53298228
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16728892.7T PL3302499T3 (pl) | 2015-06-05 | 2016-06-03 | Leczenie chorób mitochondrialnych |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US11337980B2 (pl) |
| EP (2) | EP4218938A1 (pl) |
| JP (4) | JP6885544B2 (pl) |
| CN (2) | CN107820430A (pl) |
| AU (2) | AU2016273340B2 (pl) |
| BR (1) | BR112017025839A2 (pl) |
| CA (1) | CA2991271C (pl) |
| CY (1) | CY1126058T1 (pl) |
| DK (1) | DK3302499T3 (pl) |
| ES (1) | ES2944551T3 (pl) |
| FI (1) | FI3302499T3 (pl) |
| HR (1) | HRP20230277T1 (pl) |
| HU (1) | HUE062134T2 (pl) |
| IL (3) | IL289747B2 (pl) |
| LT (1) | LT3302499T (pl) |
| MX (2) | MX2017015566A (pl) |
| PL (1) | PL3302499T3 (pl) |
| PT (1) | PT3302499T (pl) |
| RS (1) | RS64273B1 (pl) |
| RU (1) | RU2745611C2 (pl) |
| SI (1) | SI3302499T1 (pl) |
| WO (1) | WO2016193421A1 (pl) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4218938A1 (en) * | 2015-06-05 | 2023-08-02 | Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca | Treatment of mitochondrial diseases |
| EP3505174B1 (en) | 2015-06-17 | 2020-04-29 | The Trustees of Columbia University in the City of New York | Deoxynucleoside therapy for diseases caused by unbalanced nucleotide pools including mitochondrial dna depletion syndromes |
| WO2022204555A1 (en) | 2021-03-26 | 2022-09-29 | Zogenix Mds, Inc. | Aqueous solutions containing purines and pyrimidines and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5246708A (en) | 1987-10-28 | 1993-09-21 | Pro-Neuron, Inc. | Methods for promoting wound healing with deoxyribonucleosides |
| ZA892928B (en) * | 1988-04-25 | 1991-01-30 | Pro Neuron Inc | Pharmaceutical compositions containing deoxyribonucleosides for wound healing |
| IT1247510B (it) * | 1991-04-19 | 1994-12-17 | Univ Cagliari | Composizioni terapeutiche ad attivita' anti-hiv costituite da 2',3'-didesossiadenosina e sostanze inibitrici della adenosina-deaminasi |
| JPH0635389A (ja) | 1992-07-20 | 1994-02-10 | Fujitsu Ltd | ホログラム記録材料 |
| US20020006913A1 (en) * | 1997-11-04 | 2002-01-17 | Von Borstel Reid W. | Antimutagenic compositions for treatment and prevention of photodamage to skin |
| US6472378B2 (en) * | 1998-08-31 | 2002-10-29 | Pro-Neuron, Inc. | Compositions and methods for treatment of mitochondrial diseases |
| NZ513926A (en) * | 1999-02-23 | 2001-09-28 | Univ California | Methods of treatment of mitochondrial disorders |
| JP2012525399A (ja) * | 2009-04-28 | 2012-10-22 | エジソン ファーマシューティカルズ， インコーポレイテッド | トコトリエノールキノンを用いる、レーバー遺伝性視神経症および優性遺伝性視神経萎縮症の治療 |
| US20150065556A1 (en) * | 2013-08-05 | 2015-03-05 | Whitehead Institute For Biomedical Research | Therapeutic targets for mitochondrial disorders |
| CN104524546B (zh) * | 2014-12-18 | 2019-06-21 | 中国科学院广州生物医药与健康研究院 | 用于治疗Alpers-Huttenlocher综合征的药物组合物 |
| EP4218938A1 (en) * | 2015-06-05 | 2023-08-02 | Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca | Treatment of mitochondrial diseases |
-
2016
- 2016-06-03 EP EP23156608.4A patent/EP4218938A1/en active Pending
- 2016-06-03 PL PL16728892.7T patent/PL3302499T3/pl unknown
- 2016-06-03 IL IL289747A patent/IL289747B2/en unknown
- 2016-06-03 LT LTEPPCT/EP2016/062636T patent/LT3302499T/lt unknown
- 2016-06-03 SI SI201631688T patent/SI3302499T1/sl unknown
- 2016-06-03 AU AU2016273340A patent/AU2016273340B2/en active Active
- 2016-06-03 ES ES16728892T patent/ES2944551T3/es active Active
- 2016-06-03 CN CN201680039230.6A patent/CN107820430A/zh active Pending
- 2016-06-03 US US15/578,621 patent/US11337980B2/en active Active
- 2016-06-03 HR HRP20230277TT patent/HRP20230277T1/hr unknown
- 2016-06-03 IL IL320960A patent/IL320960A/en unknown
- 2016-06-03 CA CA2991271A patent/CA2991271C/en active Active
- 2016-06-03 FI FIEP16728892.7T patent/FI3302499T3/fi active
- 2016-06-03 WO PCT/EP2016/062636 patent/WO2016193421A1/en not_active Ceased
- 2016-06-03 RU RU2018123532A patent/RU2745611C2/ru active
- 2016-06-03 BR BR112017025839-0A patent/BR112017025839A2/en not_active Application Discontinuation
- 2016-06-03 JP JP2017562304A patent/JP6885544B2/ja active Active
- 2016-06-03 PT PT167288927T patent/PT3302499T/pt unknown
- 2016-06-03 RS RS20230259A patent/RS64273B1/sr unknown
- 2016-06-03 CN CN202411538223.3A patent/CN119386033A/zh active Pending
- 2016-06-03 HU HUE16728892A patent/HUE062134T2/hu unknown
- 2016-06-03 MX MX2017015566A patent/MX2017015566A/es unknown
- 2016-06-03 EP EP16728892.7A patent/EP3302499B1/en active Active
- 2016-06-03 DK DK16728892.7T patent/DK3302499T3/da active
-
2017
- 2017-11-29 IL IL255988A patent/IL255988B/en unknown
- 2017-12-01 MX MX2022012719A patent/MX2022012719A/es unknown
-
2021
- 2021-04-28 JP JP2021075504A patent/JP2021121594A/ja active Pending
- 2021-12-08 AU AU2021282462A patent/AU2021282462B2/en active Active
-
2022
- 2022-04-25 US US17/728,698 patent/US11998551B2/en active Active
-
2023
- 2023-05-26 CY CY20231100251T patent/CY1126058T1/el unknown
- 2023-05-30 JP JP2023088479A patent/JP2023123444A/ja active Pending
-
2024
- 2024-05-01 US US18/652,660 patent/US20250099473A1/en active Pending
-
2025
- 2025-07-25 JP JP2025124734A patent/JP2025172733A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3283527T3 (pl) | Leczenie skojarzone nowotworów | |
| IL263680A (en) | Combination therapies | |
| PL3265053T3 (pl) | Sposoby leczenia skóry | |
| EP3448263A4 (en) | ELECTROTHERAPEUTIC TREATMENT | |
| DK3212233T3 (da) | Kombinationsterapi til behandling af sygdom | |
| PL3288581T3 (pl) | Sposób leczenia nowotworu | |
| EP3291824C0 (en) | ANTIMICROBIAL THERAPY | |
| PL3212174T3 (pl) | Sposoby leczenia zakażeń wirusem filoviridae | |
| EP3875139C0 (en) | TREATMENT OF VENOUS DISEASES | |
| PL3169328T3 (pl) | Pochodne chinoliny do leczenia chorób zapalnych | |
| HUE056287T2 (hu) | Pancreatitis kezelése | |
| HUE059303T2 (hu) | Acetilkolin-észteráz-gátlók bõrbetegségek kezelésére | |
| EP3273955A4 (en) | TREATMENT OF RESPIRATORY DISEASES | |
| PT3622953T (pt) | Tratamento combinado do cancro | |
| HUE051296T2 (hu) | Benzoxazinon-származékok bõrbetegségek kezelésére | |
| EP3375108A4 (en) | SELECTIVE WIFI | |
| LT3119384T (lt) | Intrahepatinių cholestazinių ligų gydymas | |
| IL257764B (en) | Methods for treatment of diseases | |
| DK3283210T3 (da) | Fremgangsmåde | |
| LT3576740T (lt) | Vėžio gydymas | |
| IL246558A0 (en) | Novel methods for treating cancer | |
| IL254825A0 (en) | Methods of treatment with taselisib | |
| EP3493821A4 (en) | METHOD OF TREATING THE RESPIRATORY TRACT | |
| SI3458067T1 (sl) | Zdravljenje nevroloških obolenj | |
| HUE063820T2 (hu) | Módszerek kardiovaszkuláris betegségek kezelésére |